Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 14,028	$ 6,919	$ 32,104	$ 20,833
General and administrative	2,702	3,416	9,275	7,575
Total operating expenses	16,730	10,335	41,379	28,408
Loss from operations	(16,730)	(10,335)	(41,379)	(28,408)
Other income (expense), net	(75)	61	(123)	130
Net loss	$ (16,805)	$ (10,274)	$ (41,502)	$ (28,278)
Net loss per share, basic	$ (0.92)	$ (0.64)	$ (2.48)	$ (2.69)
Net loss per share, diluted	$ (0.92)	$ (0.64)	$ (2.48)	$ (2.69)
Weighted average common shares outstanding, basic	18,287,924	15,984,609	16,768,458	10,505,826
Weighted average common shares outstanding, diluted	18,287,924	15,984,609	16,768,458	10,505,826
Comprehensive loss:
Net loss	$ (16,805)	$ (10,274)	$ (41,502)	$ (28,278)
Other comprehensive loss:
Unrealized gain (loss) on marketable debt securities	(1)	1	(1)	(2)
Total other comprehensive loss	(1)	1	(1)	(2)
Total comprehensive loss	$ (16,806)	$ (10,273)	$ (41,503)	$ (28,280)